Related Experiment Video
Updated: Dec 16, 2025
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
Identifying States of Collateral Sensitivity during the Evolution of Therapeutic Resistance in Ewing's Sarcoma
Jessica A Scarborough1, Erin McClure2, Peter Anderson3
1Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44106, USA; Systems Biology and Bioinformatics Department, School of Medicine, Case Western Reserve University, Cleveland OH 44106, USA.
Abstract:
Advances in the treatment of Ewing's sarcoma (EWS) are desperately needed, particularly in the case of metastatic disease. A deeper understanding of collateral sensitivity, where the evolution of therapeutic resistance to one drug aligns with sensitivity to another drug, may improve our ability to effectively target this disease. For the first time in a solid tumor, we produced a temporal collateral sensitivity map that demonstrates the evolution of collateral sensitivity and resistance in EWS. We found that the evolution of collateral resistance was predictable with some drugs but had significant variation in response to other drugs. Using this map of temporal collateral sensitivity in EWS, we can see that the path toward collateral sensitivity is not always repeatable, nor is there always a clear trajectory toward resistance or sensitivity. Identifying transcriptomic changes that accompany these states of transient collateral sensitivity could improve treatment planning for patients with EWS.
Insights
Understanding collateral sensitivity in Ewing sarcoma (EWS) is key for new treatments. This study maps how EWS evolves drug resistance and sensitivity, revealing unpredictable patterns that could guide future therapies.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Ewing's sarcoma (EWS) treatment, especially for metastatic cases, requires significant advancements.
- Collateral sensitivity, a phenomenon where resistance to one drug confers sensitivity to another, offers a potential therapeutic strategy.
- Understanding the dynamic interplay between drug resistance and sensitivity is crucial for effective EWS targeting.
Purpose of the Study:
- To create the first temporal collateral sensitivity map for a solid tumor, specifically EWS.
- To investigate the evolution of collateral sensitivity and resistance in EWS.
- To identify transcriptomic changes associated with transient collateral sensitivity states in EWS.
Main Methods:
- Development of a temporal collateral sensitivity map in EWS models.
- Analysis of drug resistance and sensitivity evolution over time.
- Transcriptomic profiling to identify molecular changes linked to collateral sensitivity.
Main Results:
- Demonstrated the evolution of collateral sensitivity and resistance in EWS.
- Observed predictable collateral resistance patterns with certain drugs, but significant variability with others.
- Highlighted that the trajectory toward collateral sensitivity or resistance in EWS is not always repeatable or linear.
Conclusions:
- The study provides a novel temporal collateral sensitivity map for EWS.
- The unpredictable nature of collateral sensitivity evolution in EWS necessitates tailored therapeutic strategies.
- Identifying transcriptomic markers of transient collateral sensitivity could enhance treatment planning for EWS patients.
